2930861-48-4
2930861-48-4
Chemical Structure
Clesitamig
Synonym(s): ALPS-12; RG-6524; RO 7616789
- CAS No.: 2930861-48-4
- Formula:N/A
- Molecular Weight:(195.836 kDa)
SMILES: [Clesitamig]
Biological Activity: Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Clesitamig | 99.78% | Clesitamig (ALPS-12) is a trispecific T cell engager with two CD3/CD137 dual-specific Fabs and one DLL3 Fab. Clesitamig engages CD3 and CD137 on T cells to activate and co-stimulate T cells, promoting their proliferation, survival, and antitumor activity. Clesitamig binds to DLL3 on tumor cells for tumor-specific recognition. Clesitamig can be used for the research of small cell lung cancer (SCLC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kang J, et al. Immune cell engagers in lung cancer. Front Immunol. 2026 Apr 10;17:1746093. [Content Brief]
- [2]. Hirofumi Mikami, et al. Abstract 1872: A DLL3/CD3/CD137 trispecific T cell engager shows potent antitumor activity in small cell lung cancer models. Cancer Res (2023) 83 (7_Supplement): 1872.
